It is well known that complex interactions exist among insulin, insulin resistance, iron and anemia. A mutual relationship has been identified between insulin and iron metabolism. Insulin both stimulates the synthesis of ferritin and causes a rapid and marked stimulation of iron uptake of cells by redistributing transferrin receptors from the intracellular compartment of the cell membrane to the cell surface. Regulation of iron uptake by insulin occurs in parallel with its effects on glucose transport. On the other hand, insulin action is also influenced by iron. Iron causes hyperinsulinemia and insulin resistance by inhibition of insulin internalization and actions. In fact, the initial and most common abnormality seen in conditions with iron overload is hepatic insulin resistance. In previous animal studies, it has been shown that glucose turnover increases in iron deficiency, and this increase is primarily due to enhanced peripheral insulin responsiveness. Interestingly, there are some reports indicating that low iron status increases insulin sensitivity in lacto-ovo vegetarians. In addition, phlebotomy is followed by decreases in serum glucose as well as by improvements in both beta-cell secretion and peripheral insulin action.

Insulin plays an important role in regulation of erythropoiesis both with its ability to boost activity of the transcription factor, hypoxia-inducible factor-1A (HIF-1A), and more directly as a growth factor influencing development of reticulocytes. On the other hand, some recent reports suggest that rising hemoglobin/hematocrit (hemoglobin/hematocrit) levels are a component of insulin resistance syndrome, presumably

**Age- and body mass index-dependent relationship between correction of iron deficiency anemia and insulin resistance in non-diabetic premenopausal women**

Ali Özdemir,* Can Sevinç,* Umut Selamet,* Berna Kamacı,* Sacide Atalay†

From the *Haydarpasa Numune Education and Research Hospital, Department of Internal Medicine, Istanbul, Turkey and the †Haydarpasa Numune Education and Research Hospital, Biochemical Laboratories, Istanbul, Turkey

Correspondence and reprint requests: Ali Özdemir, MD · Halk Cad. Arif Hikmetpasa · Ap. No: 76 D: 3 · Üsküdar · Istanbul · Turkey · T: +90(216) 391 56 65 · F: +90(216) 346 05 82 · alemoz2004@yahoo.com · Accepted for publication April 2007

Ann Saudi Med 2007; 27(5): 356-361

**BACKGROUND:** No prospective studies have evaluated the effects of correction of iron deficiency anemia on insulin resistance in non-diabetic premenopausal women. We investigated this relationship in 54 non-diabetic premenopausal women with iron deficiency anemia.

**SUBJECTS AND METHODS:** All patients were treated with oral iron preparations. Insulin resistance was calculated with the Homeostasis Model Assessment formula. All patients were dichotomized by the median for age and BMI to assess how the relationship between iron deficiency anemia and insulin resistance was affected by age and BMI.

**RESULTS:** Although the fasting glucose levels did not change meaningfully, statistically significant decreases were found in fasting insulin levels following anemia treatment both in the younger age (<40 years) (\( P = 0.040 \)) and in the low BMI (<27 kg/m\(^2\)) (\( P = 0.022 \)) subgroups but not in the older age (≥40 years) and the high BMI (≥27 kg/m\(^2\)) subgroups. Post-treatment fasting insulin levels were positively correlated both with BMI \( (r=0.386, \; P=0.004) \) and post-treatment hemoglobin levels \( (r=0.285, \; P=0.036) \). Regression analysis revealed that the factors affecting post-treatment insulin levels were BMI \( (P=0.001) \) and post-treatment hemoglobin levels \( (P=0.030) \).

**CONCLUSION:** Our results show that following the correction of iron deficiency anemia, insulin levels and HOMA scores decrease in younger and lean non-diabetic premenopausal women.
due to the facilitative effect of insulin on erythropoietin synthesis.\textsuperscript{12-14} Conversely, in patients with chronic renal failure, anemia has been suggested to be responsible for the insulin resistance commonly seen in these patients.\textsuperscript{15-18}

Hyperinsulinemia and insulin resistance constitute a risk factor for atherosclerotic heart diseases.\textsuperscript{19} It is commonly accepted that premenopausal women carry less risk for cardiovascular diseases essentially due to the protective effect of intrinsic estrogen hormone.\textsuperscript{20} In premenopausal women, iron deficiency, which is usually caused by menstrual loss, is a very common health problem. Some animal and human studies indicate that iron deficiency increases glucose tolerance and insulin sensitivity. In that case, low iron status in premenopausal women may exert an independent and additional protective role besides hormonal status for atherosclerotic heart diseases. To the best of our knowledge, there have not been any prospective studies reporting the effects of correction of iron deficiency anemia on insulin resistance in non-diabetic premenopausal women. In this prospective study, we investigated how insulin resistance is affected by correction of anemia and how this relationship might be affected by anthropological parameters such as age and BMI.

SUBJECTS AND METHODS

We recruited 54 anemic premenopausal women (menstruating women of reproductive age) who had iron deficiency anemia due to menstrual loss (median age, 40 years; mean age, 36.28±10.64 years; range, 15 to 52 years) for this study. Serum ferritin values below the normal range and transferrin saturation below 15% were accepted as indicators of iron deficiency. Blood hemoglobin and hematocrit values below the normal range (≤12 g/dL and ≤35%, respectively) were accepted as indicators of anemia. All patients were treated with oral iron preparations (daily 225 mg ferroglycine sulfate), and the median duration of treatment was three months. Patients were excluded from the study if they had family histories of diabetes mellitus, repeatedly had fasting venous serum glucose levels >110 mg/dL or were previously placed on iron replacement treatments. Previous medications other than iron preparations that had already being used by the patients were continued. Informed consent was obtained from each subject after approval of the experimental protocol by the local human ethics committee. For each patient included in this study, hemoglobin, hematocrit, serum iron, transferrin saturation and serum ferritin were measured in 12-hour fasting blood both prior to the onset of iron replacement and 15 days after stopping iron treatment due to improvement of anemia. Both pre-treatment and post-treatment insulin and glucose levels were measured in three different venous serum samples taken within intervals of 5 minutes after 12 hours of fasting. Insulin level was measured with the ECLIA (ElectroChemiLuminescence ImmunoAssay) method using a Roche Modular Analytics E170 machine (Elecsys insulin kit No. 12017547). Insulin resistance (IR) was calculated according to the Homeostasis Model

| Table 1. Pre- and post-treatment laboratory parameters of all patients. |
|-----------------------|-----------------------|-----------------------|
|                        | Pre-treatment         | Post-treatment        | P          |
| Hemoglobin (g/dL)      | 9.76±1.73             | 13.13±1.04            | <0.001     |
| Hematocrit (%)         | 30.26±4.25            | 39.11±2.92            | <0.001     |
| Iron (µg/dL)           | 20.94±15.14           | 83.90±27.09           | <0.001     |
| Ferritin (ng/mL)       | 5.56±4.07             | 33.40±23.76           | <0.001     |
| Transferrin saturation (%) | 4.77±4.00            | 25.94±8.85            | <0.001     |
| Glucose (mg/dL)        | 94.89±12.50           | 94.26±10.70           | 0.693      |
| Insulin (µIU/mL)       | 9.94±6.56             | 7.90±3.60             | 0.007      |
| HOMA score             | 2.40±1.80             | 1.86±0.91             | 0.009      |

| Table 2. Pre- and post-treatment laboratory parameters of low and high BMI subgroups. |
|-----------------------|-----------------------|-----------------------|
|                        | Lean BMI              | High BMI              | P          |
| Pre-treatment          |                        |                        |            |
| Hemoglobin (g/dL)      | 9.92±1.97             | 9.62±1.50             | 0.538      |
| Hematocrit (%)         | 30.55±4.95            | 30.00±3.55            | 0.639      |
| Iron (µg/dL)           | 19.58±15.79           | 22.21±14.67           | 0.527      |
| Transferrin saturation (%) | 4.58±3.92            | 4.94±4.15             | 0.747      |
| Ferritin (ng/mL)       | 5.25±3.36             | 5.83±4.67             | 0.613      |
| Fasting glucose (mg/dL) | 92.15±8.52            | 97.43±15.08           | 0.123      |
| Insulin (µIU/mL)       | 9.18±7.35             | 10.64±5.79            | 0.419      |
| HOMA score             | 2.13±1.89             | 2.64±1.71             | 0.304      |
| Post-treatment         |                        |                        |            |
| Hemoglobin (g/dL)      | 13.18±1.04            | 13.08±1.07            | 0.742      |
| Hematocrit (%)         | 39.42±2.87            | 38.81±2.98            | 0.449      |
| Iron (µg/dL)           | 80.85±26.96           | 86.54±27.42           | 0.446      |
| Transferrin saturation (%) | 24.97±7.76            | 26.85±9.81            | 0.442      |
| Ferritin (ng/mL)       | 30.05±16.21           | 36.38±28.87           | 0.338      |
| Fasting glucose (mg/dL) | 91.85±9.31            | 96.50±11.56           | 0.111      |
| Insulin (µIU/mL)       | 6.29±2.82             | 9.39±3.65             | 0.001      |
| HOMA score             | 1.43±0.87             | 2.26±0.93             | <0.001     |
Table 3. Pre- and post-treatment laboratory parameters of younger and older age subgroups.

|                  | Younger age | Older age | P       |
|------------------|-------------|-----------|---------|
| HEMOGLOBIN (g/dL)| 10.08±1.80  | 9.49±1.66 | 0.217   |
| HEMATOCRIT (%)   | 31.25±4.40  | 29.41±3.99| 0.114   |
| IRON (µg/dL)     | 19.48±15.89 | 22.21±14.61| 0.514   |
| TRANSFERRIN SATURATION (%) | 4.47±3.98 | 5.02±4.08 | 0.621   |
| FERRITIN (ng/mL) | 5.28±3.08   | 5.79±4.79 | 0.856   |
| FASTING GLUCOSE (mg/dL) | 95.04±11.16 | 94.74±13.80 | 0.935   |
| INSULIN (µIU/mL) | 10.27±7.20  | 9.65±6.08 | 0.734   |
| HOMA score       | 2.47±1.93   | 2.33±1.71 | 0.776   |
| HEMOGLOBIN (g/dL)| 13.18±0.87  | 13.08±1.19| 0.717   |
| HEMATOCRIT (%)   | 39.32±2.45  | 38.92±3.30| 0.623   |
| IRON (µg/dL)     | 83.96±25.65 | 83.66±28.73| 0.968   |
| TRANSFERRIN SATURATION (%) | 26.24±8.84 | 25.69±9.01 | 0.824   |
| FERRITIN (ng/mL) | 27.85±12.06 | 37.98±29.67| 0.123   |
| FASTING GLUCOSE (mg/dL) | 91.80±10.08 | 96.38±10.93 | 0.118   |
| INSULIN (µIU/mL) | 7.55±3.02   | 8.20±4.07 | 0.516   |
| HOMA score       | 1.74±0.79   | 1.97±1.00 | 0.355   |

Assessment (HOMA) formula: HOMA-IR=fasting glucose (mmol/L)×fasting insulin (mU/L)/22.5.

In all patients, we searched for the existence of a possible relationship between iron deficiency anemia and insulin resistance. All patients as a whole group were dichotomized by the median for age (<40 years, n=25 and ≥40 years, n=29) and BMI (<27 kg/m², n=26 and ≥27 kg/m², n=28) to assess how this relationship, if it existed, was affected by age and BMI.

Statistical analysis was conducted using the Statistical Package for Social Sciences (SPSS, Inc, Chicago, IL, USA) for Windows 10.0 programs. Results were expressed as means±standard deviation. Comparisons between pre- and post-treatment levels were made by the paired T test. Simple (Pearson) correlation coefficients between HOMA-IR and measures of variables were calculated, and a multiple linear regression analysis was performed, considering HOMA-IR as a dependent variable and all others as explanatory variables. Since the levels of HOMA-IR strictly depended on fasting insulin and glucose concentration, we did not consider these parameters in the multiple regression analysis. Results were analyzed with 95% confidence intervals and probability levels less than 0.05 were considered significant.

RESULTS

The patients included in this study had a mean BMI of 26.84±5.95 kg/m², a mean waist/hip ratio of 0.82±0.10 and mean age of 36.28±10.64 years. When all 54 patients were assessed as a whole, statistically significant decreases were found in fasting insulin levels and HOMA scores following the correction of iron deficiency anemia while pre-and post-treatment fasting glucose levels did not change meaningfully (Table 1). In the presence of anemia, neither fasting insulin levels nor HOMA scores were found to be significantly correlated with either hematological or iron parameters. After correction of the anemia, both fasting insulin levels and HOMA scores were found to be positively correlated with both BMI and post-treatment hemoglobin levels, with statistical significance. In the regression analysis, the factors affecting post-treatment insulin levels were found to be BMI (P=0.001) and post-treatment hemoglobin levels (P=0.030).

When all the patients were dichotomized by the median for BMI into two subgroups as low (mean BMI, 21.90±2.62; range, 17 to 26 kg/m²) and high (mean BMI, 31.43±4.22; range, 27 to 44 kg/m²) subgroups, the high BMI subgroup consisted of older patients than the low BMI subgroup (42.50±5.51 and 29.58±10.82 years, P<0.001, respectively). Neither pre-treatment nor post-treatment levels of hemoglobin, hematocrit, serum iron, transferrin saturation, serum ferritin and fasting glucose differed significantly between the low and the high BMI subgroups. Also, pre-treatment fasting insulin levels and HOMA scores in the high and low BMI subgroups did not differ significantly from each other, but the mean post-treatment fasting insulin levels and HOMA scores were found to be significantly lower in the low BMI subgroup than in the high BMI subgroup (Table 2). The fasting glucose levels of the low and high BMI subgroups did not change meaningfully following iron treatment. After correction of the anemia, both insulin levels (from 9.18±7.35 to 6.29±2.82, P=0.022) and HOMA scores (from 2.13±1.89 to 1.43±0.67, P=0.032) in the low BMI subgroup decreased significantly, whereas decreases in insulin levels (from 10.64±5.79 to 9.39±3.65, P=0.150) and HOMA scores (from 2.64±1.71 to 2.26±0.93, P=0.145) in the high BMI subgroup were less evident and statistically insignificant.

When all patients were dichotomized by the median for age into two subgroups as younger (mean age, 26.92±8.16; range, 15 to 39 years) and older (mean age ≥27 kg/m², n=28) to assess how this relationship, if it existed, was affected by age and BMI.

Statistical analysis was conducted using the Statistical Package for Social Sciences (SPSS, Inc, Chicago, IL, USA) for Windows 10.0 programs. Results were expressed as means±standard deviation. Comparisons between pre- and post-treatment levels were made by the paired T test. Simple (Pearson) correlation coefficients between HOMA-IR and measures of variables were calculated, and a multiple linear regression analysis was performed, considering HOMA-IR as a dependent variable and all others as explanatory variables. Since the levels of HOMA-IR strictly depended on fasting insulin and glucose concentration, we did not consider these parameters in the multiple regression analysis. Results were analyzed with 95% confidence intervals and probability levels less than 0.05 were considered significant.
Patients with thalassemia and insulin resistance are multifactorial. Our results show indicators of insulin resistance seen in non-diabetic patients following treatment of iron deficiency anemia and insulin resistance other than reports indicating that low iron status enhances insulin sensitivity in lacto-ovo vegetarians. 5–9 

The most important result of this study is that the relationship between iron deficiency anemia and insulin resistance is multifactorial. Our results show that some anthropological parameters such as age and BMI have an influence on the relationship between iron deficiency anemia and insulin levels.

When all 54 patients were assessed as a whole, the results of this study differed from the results of animal experiments showing that iron deficiency increases glucose tolerance primarily due to an increase in peripheral insulin responsiveness. 5–9 Similar studies have also been done with chronic renal failure patients in whom insulin resistance is accompanied with many other factors. 15,17,27 Anemia has been suggested as the causal factor for insulin resistance in these patients. Moreover, it has been reported that insulin resistance is reduced or improved in these patients due to either the direct effect of erythropoietin treatment or the indirect effect of anemia correction. 15,16,27 With respect to anemia, our results are similar to the results of the studies done with patients with chronic renal failure. However, our results indicate that neither low iron status itself nor the resultant anemia of iron deficiency are the causes of the higher insulin levels and HOMA scores.

In this study, the results of the subgroup analysis for age and BMI suggest that the anthropological characteristics of a study population may affect the relationship between iron deficiency anemia and insulin resistance, so the contrary results found in this study could be due to the different anthropological characteristics of the study population. The reason for the different responses in means of insulin resistance to iron treatment exerted by the younger age/low BMI and the older age/high BMI subgroups is not clear given that subjects were of the same gender and had similar hormonal status. We speculate that patients of younger age and low BMI are more energetic and active following the treatment of anemia compared to patients of older age and higher BMI, and the expenditure of more energy might be an additional factor contributing to the reduction of insulin resistance. Also, the therapy duration of three months is not long enough to see the changes in the levels of insulin and HOMA scores in patients with older age and high BMI who already have established insulin resistance when compared with patients of younger age and low BMI. The results of these subgroup analyses indicate both the necessity of taking the anthropological characteristics of the study population into account.
while assessing the relationship between iron deficiency and insulin resistance, and the need for further studies with different population groups.

On the other hand, there are some recent reports suggesting that the rising of hemoglobin/hematocrit values might be a component of the insulin resistance syndrome. In this study, we also found that there were statistically significant positive correlations between post-treatment hemoglobin levels and insulin levels as well as between post-treatment hemoglobin levels and HOMA scores. Also, regression analysis revealed that the factors affecting post-treatment insulin levels were BMI and post-treatment hemoglobin levels. These results of regression and correlation analyses provide support for the existence of a relationship between insulin resistance and hematological parameters. Therefore, when considering the treatment of iron deficiency anemia, targeting lower hemoglobin/hematocrit levels may be a suitable and a necessary action for patients of older age and higher BMI who already have established insulin resistance, and particularly for the patients in whom impaired glucose tolerance accompanies iron deficiency.

We do not know the exact underlying mechanism that explains the significant decrease in fasting insulin levels and HOMA scores after the treatment of iron deficiency anemia in premenopausal women. Also, we do not know whether the decrease in insulin levels and HOMA scores following iron therapy is due to iron replacement itself or correction of the resultant anemia. Although there are some reports showing that insulin promotes the synthesis of erythropoietin by boosting the activity of HIF-1A, which functions physiologically as a detector of both hypoxia and iron-deficiency, and induces the synthesis of glucose transporters as well as glycolytic enzymes, it is not known whether diminished activity of HIF-1A following iron therapy affects the synthesis and secretion of insulin or not. Such a relationship, if it exists, could be responsible for the decrease in insulin levels and HOMA scores following iron replacement, so it is clear that this topic merits further investigation.

Due to the role of insulin resistance and iron-dependent oxidative stress in the onset and progression of atherosclerosis, the relationship between iron deficiency and insulin resistance has importance. Despite some contrary reports, it has been shown that there is a link between iron status and the pathogenesis of atherosclerosis. Also, some evidence from previously published data show that the progression of an atherosclerotic plaque can be decelerated by reducing body iron stores with phlebotomy. When the results of our study are assessed in this perspective, it can be concluded that iron deficiency has a reducing effect on insulin levels in patients of younger age and lower BMI in whom atherosclerosis and its complications are expected to be less prevalent, whereas such an effect was not evident in patients of older age and higher BMI in whom atherosclerosis and its complications are expected to be more prevalent. This result is not compatible with the hypothesis that low iron status in premenopausal women may play an independent and additional protective role for atherosclerotic heart diseases.

In conclusion, our results show that an age- and BMI-dependent relationship exists between iron deficiency anemia and insulin levels (and HOMA scores) in non-diabetic premenopausal women. When considering the treatment of iron deficiency anemia, targeting lower hemoglobin/hematocrit levels may be an appropriate and a necessary action for the patients of older age and higher BMI, particularly for patients in whom impaired glucose tolerance accompanies iron deficiency.
REFERENCES

1. Davis RJ, Covera S, Czech MP: Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 1986, 261: 8708-8711.

2. Tanner LI, Linhard GE: Localization of transferrin receptors and insulin-like growth factor II receptors in vesicles from 3T3-L1 adipocytes that contain intracellular glucose transporters. J Cell Biol 1989, 108: 1537-1545.

3. Fernández-Real JM, López-Bermejo A, Ricart W: Cross-Talk Between Iron Metabolism and Diabetes. Diabetes 2002, 51:2348-2354.

4. Dandona P, Hussain MAM, Varghese Z, Politis D, Rynn DM, Hoffbrand AV: Insulin resistance and iron overload. Ann Clin Biochem 1983, 20:77-79.

5. Borel MJ, Beard JL, Farrell PA: Hepatic glucose production and insulin sensitivity and responsiveness in iron deficient anemic rats. Am J Physiol. 1993 Mar;264(3 Pt 1):E380-90.

6. Brooks GA, Henderson SA, Dallman PR: Increased glucose dependence in resting, iron-deficient rats. Am J Physiol. 1987 Oct;253(4 Pt 1):E461-6.

7. Henderson SA, Dallman PR, Brooks GA: Glucose turnover and oxidation are increased in the iron-deficient anemic rat. Am J Physiol. 1986 Apr;250(4 Pt 1):E414-21.

8. Klemper KL, Willis WT, Chengson R, Dallman PR, Brooks GA: Iron deficiency decreases glucokinase expression in isolated rat hepatocytes. J Appl Physiol. 1989 Nov;67(5):1868-72.

9. Hua NW, Stoothers RA, Facchini FS: Low iron status and enhanced insulin sensitivity in lacto-ovo vegetarians. Br J Nutr. 2001 Oct;86(4):1515-9.

10. Facchini FS: Effect of phlebotomy on plasma glucose and insulin concentrations. Diabetes Care 1998, 21:2190.

11. McCarty MF: Hyperinsulinemia may boost both hemocrit and iron absorption by up-regulating activity of hypoxia-inducible factor-1alpha. Med Hypotheses. 2003 Nov-Dec;61(5-6):567-73.

12. Barbieri M, Ragno E, Benvenuti E, Zito CA, Corsi A, Ferrucci L, et al: New aspects of the insulin resistance syndrome: impact on haematological parameters. Diabetologia. 2001 Oct;44(10):1232-7.

13. Choi KM, Lee J, Kim HY, Kim KB, Kim DK, Kim SG, et al: Relation between insulin resistance and hematological parameters in elderly Koreans-Southwest Seoul (SWS) Study. Diabetes Res Clin Pract. 2003 Jun;60(3):205-12.

14. Zidek V, Fucikova A, Musilova A, Bila V, Kren V, Pravenec M: Hematocrit and hemoglobin values are negatively correlated with insulin resistance in spontaneous hypertension. Folia Biol (Praha). 1999;45(6):247-51.

15. Mak RH: Metabolic effects of erythropoietin in patients on peritoneal dialysis. Pediatr Nephrol. 1998 Oct;12(6):660-5.

16. Mak RH: Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. J Pediatr. 1996;129(1):97-104.

17. Mak RH: Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia. Am J Physiol. 1996 May;270(5 Pt 2):F839-44.

18. Igaki N, Takashima M, Ohyama M, Oh S, Kida A, Yanase K, et al: The beneficial effect of effective control of anemia on hyperinsulinemia and serum iron concentration in a hemodialysis patient with corrected transposition of the great arteries. Clin Exp Nephrol. 2004 Jun;8(2):163-7.

19. Yoon KH, Jeong MH, Kim KH, Hong YJ, Park HW, Kim JH, et al: The effect of insulin resistance on progression of non-diabetic patients who underwent percutaneous transluminal coronary intervention. J Korean Med Sci. 2008 Apr;23(4):232-6.

20. Shirah JM, Khalil RA: Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol. 2004 Feb;286(2):R223-49.

21. Khalifa AS, Salem M, Mourin E, El-Tawil MM, El-Sawy M, Abd Al-Aziz MM: Normal glucose tolerance in Egyptian beta-thalassemia patients: possible association with genotype. Pediatr Diabetes. 2004 Sep;5(3):125-22.

22. Messina FM, Lombardo F, Meo A, Miceli M, Wasniewska V, Valenzise M, et al: Three-year prospective evaluation of glucose tolerance, beta-cell function and peripheral insulin sensitivity in non-diabetic patients with thalassemia major. J Endocrinol Invest. 2002 Jun;25(6):497-501.

23. Pappas S, Donohue SM, Denver AE, Mohamed-Ali V, Goubet S, Youk JS: Glucose intolerance in thalassemia major is related to insulin resistance and hepatic dysfunction. Metabolism. 1996 May;45(5):652-7.

24. Dmochowski K, Finegood DT, Francombe W, Tyler B, Ziman B: Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab. 1993 Aug;71(2):478-83.

25. Wajnrajch MP, Gertner JM, Huma Z, Popovic J, Lin K, Verlander FC, et al: Evaluation of growth and hormonal status in patients referred to the International Fanconi Anemia Registry. Pediatr. 2001 Apr;107(4):744-54.

26. Vantyghem MC, Girardot C, Boulouge A, Weaume JL: Iron overload and insulin resistance. Presse Med 2005 Nov 5; 34(19 Pt 1):1391-8.

27. Spina S, Pangalis M, Askepidou N, Pazarloglou M, Mavropoulou E, Theodoridis S, et al: Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron. 2000 Apr;84(4):320-5.

28. Dabbagh AJ, Shwaery GT, Keaney JF Jr, Frei B: Effect of iron overload and iron deficiency on atherosclerosis in the hypercholesterolemic rabbit. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2638-45.

29. Asian M, Koseck M, Horoz M, Selek S, Celik H, Erel O: Assessment of paraoxonase and antileukase activities in patients with iron deficiency anemia. Atherosclerosis. 2006 May 6; [Epub ahead of print]

30. You SA, Wang Q: Ferritin in atherosclerosis. Clin Chim Acta. 2005 Jul 1;357(1):1-16.

31. Dayrums R, Schulman P: Iron and atherosclerosis. Clin Cardiol. 2005 Mar;28(3):119-22.

32. Mingin R, Rajendran R, Pan N, Tan BK, Ong WW, Watt F, et al: The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic Biol Med. 2005 May 1;38(9):1206-11.

33. Sengoeige G, Sunder-Plassmann G, Horl WH: Potential risk for infection and atherosclerosis due to iron therapy. J Ren Nutr. 2005 Jan;15(1):105-10.

34. Kruszewski M: The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol. 2004;51(2):471-80.

35. Yuan XM, Lu W: The iron hypothesis of atherosclerosis and its clinical impact. Ann Med. 2003;35(8):578-91.

36. Zheng H, Cable R, Spencer B, Votto N, Katz SD: Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol. 2005 Aug; 25(8):1577-83.